Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
77.50
-0.35 (-0.45%)
Apr 10, 2026, 4:00 PM EDT - Market closed
Nektar Therapeutics Revenue
In the year 2025, Nektar Therapeutics had annual revenue of $55.23M, down -43.89%. Nektar Therapeutics had revenue of $21.81M in the quarter ending December 31, 2025, a decrease of -25.25%.
Revenue (ttm)
$55.23M
Revenue Growth
-43.89%
P/S Ratio
40.25
Revenue / Employee
$876,698
Employees
63
Market Cap
2.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 55.23M | -43.20M | -43.89% |
| Dec 31, 2024 | 98.43M | 8.31M | 9.22% |
| Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
| Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
| Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
| Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
| Dec 31, 2019 | 114.62M | -1.08B | -90.40% |
| Dec 31, 2018 | 1.19B | 885.61M | 287.81% |
| Dec 31, 2017 | 307.71M | 142.28M | 86.00% |
| Dec 31, 2016 | 165.44M | -65.35M | -28.32% |
| Dec 31, 2015 | 230.78M | 30.08M | 14.99% |
| Dec 31, 2014 | 200.71M | 51.79M | 34.77% |
| Dec 31, 2013 | 148.92M | 67.73M | 83.42% |
| Dec 31, 2012 | 81.19M | 9.71M | 13.59% |
| Dec 31, 2011 | 71.48M | -87.56M | -55.06% |
| Dec 31, 2010 | 159.04M | 87.11M | 121.10% |
| Dec 31, 2009 | 71.93M | -18.25M | -20.24% |
| Dec 31, 2008 | 90.19M | -182.84M | -66.97% |
| Dec 31, 2007 | 273.03M | 55.31M | 25.40% |
| Dec 31, 2006 | 217.72M | 91.44M | 72.41% |
| Dec 31, 2005 | 126.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.20B |
| Ultragenyx Pharmaceutical | 673.00M |
| ADMA Biologics | 510.17M |
| Zai Lab | 460.16M |
| Aurinia Pharmaceuticals | 283.06M |
| Stoke Therapeutics | 184.42M |
| Syndax Pharmaceuticals | 172.35M |
| Day One Biopharmaceuticals | 158.18M |
NKTR News
- 4 days ago - NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline - GlobeNewsWire
- 12 days ago - NKTR Stockholders Have Rights – If You Lost Money Investing in Nektar Therapeutics Contact Robbins LLP for Information About Recovering Your Losses - GlobeNewsWire
- 15 days ago - Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting - PRNewsWire
- 23 days ago - Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting - PRNewsWire
- 4 weeks ago - Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire
- 4 weeks ago - NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With Large Losses in Nektar Therapeutics Should Contact Bernstein Liebhard LLP To Discuss Their Rights - GlobeNewsWire
- 5 weeks ago - Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Nektar Therapeutics, (NKTR) - Newsfile Corp
- 5 weeks ago - Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire